查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370956

栓塞治療市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按產品、適應症、程序、最終用戶、地區和競爭細分

Embolotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Indication, By Procedure, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 189 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年全球栓塞治療市場估值為 36.7 億美元，預計在預測期內將大幅成長，年複合成長率(CAGR) 為 8.35%，預計到 2028 年將達到 59.9 億美元。選擇性地限制血液流向特定區域的侵入性治療正在全球獲得認可和普及。這種血管內手術用於閉塞異常血管，有效控制或止血。在嚴重出血的緊急情況下，栓塞療法正成為侵入性手術的可行替代方案，特別是對於嚴重出血等情況。介入放射科醫師在各種臨床環境中執行此程序。栓塞療法的應用已顯著擴大，特別是在用於治療良性前列腺增生的前列腺動脈栓塞術（PAE）和用於減肥的胃動脈栓塞術（GAE）等尖端手術中。這些程序已被證明可以有效治療各自的病症。例如，全球範圍內進行 PAE 治療，以解決 BPH 引起的下泌尿道症狀 (LUTS)，每年進行 800 多例手術。栓塞療法也用於治療慢性疼痛、治療子宮肌瘤以及治療特定類型的癌症，例如肝癌。

主要市場促進因素

不斷成長的目標患者群體

市場概況
預測期 2024-2028
2022 年市場規模 36.7億美元
2028 年市場規模 59.9億美元
2023-2028 年CAGR 8.35%
成長最快的細分市場 栓塞劑
最大的市場 北美洲

心血管疾病（CVD）的流行和成功治療的重要性日益增加，導致人們開始關注有效干預措施的研究。 2017年，週邊血管疾病影響了全球超過2億人。隨著年齡的成長，這些疾病的盛行率不斷上升，尤其是在80歲及以上的老年人中。對栓塞治療設備的需求是由其成功率、術後併發症低以及肝癌和肝細胞癌等疾病發病率上升所推動的。肝癌是男性和女性最常見的癌症之一，2018 年全球新診斷病例超過 84 萬例。腎癌發生率也有所增加，特別是在英國。這些趨勢增加了對栓塞療法的需求。

患者對微創手術的偏好不斷上升

人們對微創手術的日益青睞正在推動對栓塞療法等手術的需求。患者選擇這些手術是因為術後疼痛減輕、併發症更少、住院時間更短、恢復時間更快。經動脈化療栓塞 (TACE) 等技術正在作為微創替代方案不斷發展，徹底改變了肝細胞癌等治療方法。攝護腺動脈栓塞術（PAE）是治療良性攝護腺增生（BPH）及其相關症狀的微創療法。人們對這些手術的日益青睞正在擴大栓塞治療市場。

政府和私人組織的資助和投資

充足的資金和投資推動了栓塞療法等醫療程序的研究、開發和改進。積極的試驗結果給醫療專業人員和患者帶來了信心，推動了採用的需求。培訓計劃和醫學教育向專業人員傳播知識，導致需求增加。政府的資助和支持影響保險範圍和報銷政策，使栓塞治療更容易獲得。

栓塞治療設備的技術進步

栓塞治療設備的技術進步提高了精確度、有效性和微創品質。增強型微導管、先進的影像技術、導航系統、機器人和視覺化工具已經改變了這個領域。這些進步改善了手術結果、病人安全和恢復時間。隨著技術的發展，栓塞治療領域可能會看到進一步的創新來增強這些程序。

主要市場挑戰

嚴格的規定

人工栓塞裝置被歸類為醫療器械，並受到嚴格的監管。監管分類影響器械核准和授權，進而影響市場格局。

缺乏熟練的醫療專業人員

缺乏熟練的專業人員可能會限制栓塞療法的獲得，影響患者的治療結果並增加風險。

主要市場趨勢

增加收購和合作

合作增強了栓塞治療的研究、開發、可近性和意識。協作努力加速創新和針對不同患者需求量身定做的解決方案。

腫瘤學進展

創新癌症治療的需求推動了對栓塞療法等個人化解決方案的需求。精確性和微創性使栓塞療法在個人化腫瘤護理中具有吸引力。

細分市場洞察

產品洞察

由於需要微球的疾病越來越普遍，特別是在肝細胞癌治療中，栓塞劑領域佔據了市場主導地位。

最終使用者見解

醫院是栓塞治療設備的主要使用者。微創手術的使用不斷增加、醫療保健提供者的購買力不斷增強以及報銷的可用性有助於該細分市場的成長。

區域洞察

北美洲

由於需要栓塞治療的疾病普遍存在、完善的醫療保健系統以及栓塞劑的不斷進步，北美在市場上處於領先地位。

亞太

由於患者人數增加、政府醫療投資和癌症發病率上升，亞太地區預計將經歷最快的成長。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球栓塞治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品（栓塞劑、微導管）
    • 依適應症（腫瘤科、血管科、動脈瘤科、泌尿科、腎臟科）
    • 按程序（TACE、TARE）
    • 按最終使用者（醫院、診所、門診手術中心）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：北美栓塞治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按指示
    • 按程式
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲栓塞治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按指示
    • 按程式
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區栓塞治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按指示
    • 按程式
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲栓塞治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按指示
    • 按程式
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲栓塞治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按指示
    • 按程式
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非栓塞療法
    • 沙烏地阿拉伯栓塞療法
    • 阿拉伯聯合大公國栓塞療法

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 13 章：全球口腔臨床營養市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 服務內容
  • 最近的發展
  • 主要人員
  • SWOT分析
    • Medtronic, PLC
    • Microport Scientific
    • Boston Scientific Corporation
    • Stryker
    • Terumo Corporation
    • Penumbra, Inc.
    • Sirtex (CDH)
    • Johnson & Johnson
    • Abbott Laboratories
    • Balt Group

第 16 章：策略建議

第 17 章：關於我們與免責聲明

簡介目錄
Product Code: 4666

The Global Embolotherapy Market was valued at USD 3.67 Billion in 2022 and is expected to experience substantial growth in the forecast period, with a Compound Annual Growth Rate (CAGR) of 8.35% and expected to reach USD 5.99 Billion through 2028. Embolotherapy, a minimally invasive treatment that selectively restricts blood flow to specific areas, is gaining recognition and popularity globally. This endovascular procedure is utilized to occlude abnormal blood vessels, effectively controlling or stopping bleeding. In urgent cases of severe hemorrhage, Embolotherapy is emerging as a viable alternative to invasive surgery, particularly for cases like severe bleeding. Interventional radiologists perform this procedure in various clinical settings. The applications of Embolotherapy have expanded significantly, especially in cutting-edge procedures like prostatic artery embolization (PAE) for benign prostatic hyperplasia and gastric artery embolization (GAE) for weight loss. These procedures have proven to be effective in treating their respective conditions. For instance, PAE is performed globally to address lower urinary tract symptoms (LUTS) caused by BPH, with over 800 procedures annually. Embolotherapy is also used in managing chronic pain conditions, treating uterine fibroids, and addressing specific types of cancer, such as liver cancer.

Key Market Drivers

Growing Target Patient Population

Market Overview
Forecast Period2024-2028
Market Size 2022USD 3.67 Billion
Market Size 2028USD 5.99 Billion
CAGR 2023-20288.35%
Fastest Growing SegmentEmbolic Agents
Largest MarketNorth America

The prevalence of cardiovascular disease (CVD) and the increasing importance of successful treatments have led to a focus on research into effective interventions. Peripheral vascular diseases affected over 200 million individuals globally in 2017. With age, the prevalence of these diseases rises, particularly in those aged 80 and above. The demand for Embolotherapy devices is driven by its success rate, low postoperative complications, and the rising incidence of conditions like liver cancer and hepatocellular cancer. Liver cancer is among the most common cancers in men and women, with over 840,000 new cases diagnosed worldwide in 2018. Kidney cancer incidence rates have also increased, particularly in the United Kingdom. These trends contribute to the demand for Embolotherapy.

Rising Patient Preference for Minimally Invasive Procedures

The increasing preference for minimally invasive surgeries is driving the demand for procedures like Embolotherapy. Patients opt for these procedures due to reduced postoperative pain, fewer complications, shorter hospital stays, and faster recovery times. Techniques like Trans Arterial Chemo Embolization (TACE) are evolving as minimally invasive alternatives, revolutionizing treatments like hepatocellular carcinoma. Prostatic Artery Embolization (PAE) serves as a minimally invasive therapy for benign prostatic hyperplasia (BPH) and its associated symptoms. The growing preference for these procedures is expanding the embolotherapy market.

Funding & Investments by Government and Private Organizations

Adequate funding and investments drive research, development, and refinement of medical procedures like Embolotherapy. Positive trial results instill confidence in medical professionals and patients, driving demand for adoption. Training programs and medical education disseminate knowledge among professionals, leading to increased demand. Government funding and support influence insurance coverage and reimbursement policies, making Embolotherapy more accessible.

Technological Advancements in Embolotherapy Devices

Technological advancements in embolotherapy devices have improved precision, effectiveness, and minimally invasive qualities. Enhanced microcatheters, advanced imaging techniques, navigation systems, robotics, and visualization tools have transformed the field. These advancements improve procedural outcomes, patient safety, and recovery times. As technology evolves, the embolotherapy field will likely see further innovations enhancing these procedures.

Key Market Challenges

Stringent Regulations

Artificial embolization devices are classified as medical devices and are subject to stringent regulations. Regulatory classifications impact device approval and authorization, influencing the market landscape.

Lack Of Skilled Medical Professionals

A shortage of skilled professionals can limit access to embolotherapy treatments, affecting patient outcomes and increasing risks.

Key Market Trends

Increasing Acquisitions and Collaborations

Collaborations enhance research, development, accessibility, and awareness of embolotherapy. Collaborative efforts accelerate innovation and solutions tailored to diverse patient needs.

Advancement in Oncology

The need for innovative cancer treatments drives demand for personalized solutions like embolotherapy. Precision and minimal invasiveness make embolotherapy attractive in personalized oncology care.

Segmental Insights

Product Insights

The embolic agent segment dominates the market due to the increasing prevalence of conditions requiring microspheres, especially in hepatocellular carcinoma treatment.

End User Insights

Hospitals are the primary users of embolotherapy devices. The increasing utilization of minimally invasive procedures, growing healthcare provider purchasing power, and availability of reimbursements contribute to this segment's growth.

Regional Insights

North America

North America leads the market due to the prevalence of conditions requiring embolization, a well-established healthcare system, and ongoing advancements in embolic agents.

Asia-Pacific

The Asia-Pacific region is expected to experience the fastest growth due to increasing patient populations, government healthcare investments, and rising cancer incidence.

Key Market Players

  • Medtronic, PLC
  • Microport Scientific
  • Boston Scientific Corporation
  • Stryker
  • Terumo Corporation
  • Penumbra, Inc.
  • Sirtex (CDH)
  • Johnson & Johnson
  • Abbott Laboratories
  • Balt Group

Report Scope:

In this report, the Global Embolotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Embolotherapy Market, By Product:

  • Embolic Agents
  • Microspheres
  • Liquid Embolic Agents
  • Coil
  • Microcatheters

Embolotherapy Market, By Indication:

  • Oncology
  • Vascular
  • Aneurysm
  • Urology
  • Nephrology

Embolotherapy Market, By Procedure:

  • TACE
  • TARE

Embolotherapy Market, By End User:

  • Hospital
  • Clinics
  • Ambulatory Surgery Centres

Embolotherapy Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Embolotherapy Market.

Available Customizations:

  • Global Embolotherapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Embolotherapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Embolic Agents, Microcatheters)
      • 5.2.1.1. By Embolic Agents (Microspheres, Liquid Embolic Agents, Coil)
    • 5.2.2. By Indication (Oncology, Vascular, Aneurysm, Urology, Nephrology)
    • 5.2.3. By Procedure (TACE, TARE)
    • 5.2.4. By End User (Hospital, Clinics, Ambulatory Surgery Centres)
    • 5.2.5. By Region
    • 5.2.6. By Company (2022)
  • 5.3. Market Map

6. North America Embolotherapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
      • 6.2.1.1. By Embolic Agents
    • 6.2.2. By Indication
    • 6.2.3. By Procedure
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Embolotherapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.1.1. By Embolic Agents
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By Procedure
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Embolotherapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.1.1. By Embolic Agents
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By Procedure
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Embolotherapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.1.1. By Embolic Agents
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By Procedure
        • 6.3.3.2.4. By End User

7. Europe Embolotherapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
      • 7.2.1.1. By Embolic Agents
    • 7.2.2. By Indication
    • 7.2.3. By Procedure
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Embolotherapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.1.1. By Embolic Agents
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Procedure
        • 7.3.1.2.4. By End User
    • 7.3.2. United Kingdom Embolotherapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.1.1. By Embolic Agents
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Procedure
        • 7.3.2.2.4. By End User
    • 7.3.3. Italy Embolotherapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Product
        • 7.3.3.2.1.1. By Embolic Agents
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Procedure
        • 7.3.3.2.4. By End User
    • 7.3.4. France Embolotherapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.1.1. By Embolic Agents
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By Procedure
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Embolotherapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.1.1. By Embolic Agents
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By Procedure
        • 7.3.5.2.4. By End User

8. Asia-Pacific Embolotherapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
      • 8.2.1.1. By Embolic Agents
    • 8.2.2. By Indication
    • 8.2.3. By Procedure
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Embolotherapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.1.1. By Embolic Agents
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Procedure
        • 8.3.1.2.4. By End User
    • 8.3.2. India Embolotherapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.1.1. By Embolic Agents
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Procedure
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Embolotherapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.1.1. By Embolic Agents
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Procedure
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Embolotherapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.1.1. By Embolic Agents
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Procedure
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Embolotherapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.1.1. By Embolic Agents
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Procedure
        • 8.3.5.2.4. By End User

9. South America Embolotherapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
      • 9.2.1.1. By Embolic Agents
    • 9.2.2. By Indication
    • 9.2.3. By Procedure
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Embolotherapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.1.1. By Embolic Agents
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Procedure
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Embolotherapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.1.1. By Embolic Agents
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Procedure
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Embolotherapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.1.1. By Embolic Agents
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Procedure
        • 9.3.3.2.4. By End User

10. Middle East and Africa Embolotherapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
      • 10.2.1.1. By Embolic Agents
    • 10.2.2. By Indication
    • 10.2.3. By Procedure
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Embolotherapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.1.1. By Embolic Agents
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Procedure
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Embolotherapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.1.1. By Embolic Agents
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Procedure
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Embolotherapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.1.1. By Embolic Agents
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Procedure
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Oral Clinical Nutrition Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Medtronic, PLC
    • 15.5.2. Microport Scientific
    • 15.5.3. Boston Scientific Corporation
    • 15.5.4. Stryker
    • 15.5.5. Terumo Corporation
    • 15.5.6. Penumbra, Inc.
    • 15.5.7. Sirtex (CDH)
    • 15.5.8. Johnson & Johnson
    • 15.5.9. Abbott Laboratories
    • 15.5.10. Balt Group

16. Strategic Recommendations

17. About Us & Disclaimer